(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Discovery of massive spider's web in Greece reveals unexpected behavior - 2Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- 3The Best Cell phone Brands for Tech Lovers
- 4The most effective method to Go with Informed Choices on Vehicle Leases
- 57 Fast Approaches to Let loose Space on Your Telephone in a flash
- Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this?
- The Main 15 Applications for Efficiency and Association
- The Best Computer games for Multiplayer Fun
- Family Holiday spots
- Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- Vote In favor of Your Number one Game Control center
- 5 Superstar Couples That Motivate Relationship Objectives
- The Force of Care: Living with Goal
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
